Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

Watchdog finds failings in prostate cancer treatment in North Wales going back almost a decade.

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

This may not apply in your husband’s case, but it’s worth having the conversation. The two meds Goldstein prescribes for men are flibanserin (Addyi), an oral tablet taken d ...

State data from 2018 through 2022 shows prostate cancer is the leading cancer diagnosis in Cuyahoga County, yet 77% of cases ...

What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch well beyond its original purpose? That’s exactly the twist happening with a ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

I’m sure I enjoyed them as a child, though my brain has not retained a single memory of any birthday from my youth. I do, ...